|
Session 144
Poster Abstracts
Therapy of Hepatitis C Infection
Tuesday, 1:30 - 3:30 pm
Poster Hall |
852
 |
High-dose Induction Therapy with peg-IFN-a2b + RBV Seems Not More Effective than Standard-dose peg-IFN-a2b + RBV for Treatment of HCV In HCV/HIV-co-infected Patients
T Ruys1, E Hassink2, K Ten Veen3, R Kauffmann4, C Richter5, A Van Eeden6, M Beld1, S Ding2, Ferdinand Wit*1, and J Lange1
1IATEC, Academic Med Ctr, Amsterdam, The Netherlands; 2Intl Antiviral Therapy Evaluation Ctr, Amsterdam, The Netherlands; 3OLVG, Amsterdam, Netherlands; 4Leyenburg ziekenhuis, Den Haag, Netherlands; 5Ziekenhuis Rijnstate, Arnhem, Netherlands; and 6Jan van Goyen Clin, Amsterdam, The Netherlands |
| 853 |
An Open-label, Multicenter Study of the Efficacy and Safety of Peg-interferon-A-2a Alone or in Combination with Ribavirin in Patients with HIV/HCV Co-infection
Enrique Ortega*1, A Martin1, C Barros2, J Garcia3, K Aguirrebengoa4, V Asensi5, R Rubio6, F Pulido6, J Gonzalez7, J Portu8, and M78024 Team
1Hosp Gen Univ Valencia, Spain; 2Hosp de Mostoles, Madrid, Spain; 3Hosp Virgen del Rosell, Murcia, Spain; 4Hosp de Cruces, Spain; 5Hosp Gen de Asturias, Oviedo, Spain; 6Hosp 12 de Octubre, Madrid, Spain; 7Hosp La Paz, Madrid, Spain; and 8Hosp Vitoria, Spain |
854
|
A Multicenter, Randomized Trial of 48 vs 72 Weeks of Peg-Interferon Alfa -2b + Ribavirin in HIV/HCV-co-infected Subjects: Longer Therapy Does Not Correlate with Improved Sustained Virological Response
Alison Uriel*1, L Moorehead2, D Carriero1, M Sulkowski3, D Dieterich1, and Hepatitis Resource Network Clin Trials Group
1Mt Sinai Sch of Med, New York, NY, US; 2Hepatitis Resource Network Clincal Trials Group, Puyallup, WA, US; and 3Johns Hopkins Sch of Med, Baltimore, MD, US |
855
|
Predictive Value of Early Virological Response to Treatment with Interferon-base Regimens Plus Ribavirin in HIV Patients with Chronic Hepatitis C
M Laguno, M Larrousse, J Murillas, J Blanco, E Martínez, J Sánchez-Tapias, E De Lazzari, J Costa, J Gatell, and Josep Mallolas*
Hosp Clin, Barcelona, Spain |
| 856 |
Sustained Virologic Response (SVR) in HIV-HCV Co-infected Patients with HCV Genotype 1(G1) Infection who have a Rapid Virological Response (RVR) at Week 4 of Treatment with Peginterferon Alfa-2a (40KD) (PEG IFNa-2a, PEGASYS®) Plus Ribavirin (RBV, COPEGUS®): AIDS PEGASYS Ribavirin International Co-infection Trial (APRICOT)
Douglas Dieterich*1, F Duff2, M Sulkowski3, F Torriani4, E Lissen5, N Brau6, and M Rodriguez-Torres7
1Mt Sinai Sch of Med, New York, NY, US; 2Roche, Nutley, NJ, US; 3Johns Hopkins Univ, Baltimore, MD, US; 4Univ of California, San Diego, US; 5Virgen del Rocío Univ Hosp, Seville, Spain; 6VAMC, Bronx, NY, US; and 7Fndn de Investigacion de Diego, Santurce, PR, US |
857
|
Effect of Ribavirin Trough Concentration on Early Virological Response according to HCV Genotype and on Early Hemoglobin Decrease in HCV/HIV-co-infected Patients Treated with RBV + PegIFN
Daniel Gonzalez De Requena*, A Ibanez, D Aguilar-Marucco, L Veronese, S Bonora, A D'Avolio, M Sciandra, A Sinicco, and G Di Perri
Univ of Turin, Italy |
858
|
Early Virologic Response to Pegylated Interferon and Ribavirin in a Large Cohort of HIV/HCV-co-infected Veterans
Lisa Backus*, D Boothroyd, and L Mole
Veterans Hlth Admin, Palo Alto, CA, US |
| 859 |
Sustained Virological Response Following HCV Therapy Is Associated with Regression of Liver Fibrosis in HCV/HIV-co-infected Patients
Pablo Barreiro*, N Simarro, M Nuñez, L Martin-Carbonero, M Romero, P Rivas, J García-Samaniego, J González-Lahoz, and V Soriano
Hosp Carlos III, Madrid, Spain |
| 860 |
Nadir CD4 Count Does Not Predict Response to Pegylated Interferon and Ribavirin in HIV/HCV-co-infected Patients
Susan Hopkins*1,2, O Barry2, J Turner3, M Johnson1, F Mulcahy2, R Gilson3, G Farrell2, S Bhagani1, and C Bergin2
1Royal Free Hosp Cohort, London, UK; 2St James's Hosp, Dublin, Ireland; and 3Mortimer Market Clin, London, UK |
861
|
Efficacy of Pegylated Interferon + Ribavirin in HIV/HCV Co-infection uutside of Well-circumscribed Clinical Trials: The Andalusian Multicenter Study
J Mira1, J Torre-Cisneros2, D Merino3, M Ríos4, A Collado5, S Vergara1, A Rivero2, J Lomas-Cabeza3, Juan Macías*1, J Pineda1, and the Grupo Andaluz para el Estudio de las Enfermedades Infecciosas
1Hosp de Valme, Sevilla, Spain; 2Hosp Univ Reina Sofía, Córdoba, Spain; 3Hosp Juan Ramón Jiménez, Huelva, Spain; 4Hosp Univ Virgen Macarena, Seville, Spain; and 5Hosp Torrecárdenas, Almería, Spain |
| 862 |
Rate and Predictors of Treatment for Hepatitis C
Adeel Butt*1,2, A Justice3,4, M Skanderson2, C Good2, and C Kwoh1,2
1Univ of Pittsburgh, PA, US; 2VA Pittsburgh Hlthcare System, PA, US; 3Yale Univ Med Ctr, New Haven, CT, US; and 4VA Hlthcare System, West Haven, CT, US |
| 863 |
Insulin Resistance Is a Prognostic Factor of Poor Response to Peg-interferon-Alpha 2a + Ribavirin in HCV+/HIV+ Patients
Cristina Tural*1, M Romero2, R Sola3, R Planas1, M Viloria2, M Gimenez3, A Arrizcorreta4, C Trabadela2, and B Clotet1
1Hosp Univ Germans Trias i Pujol, Barcelona, Spain; 2Hosp de Valme, Sevilla, Spain; 3Hosp del Mar, Barcelona, Spain; and 4Hosp Puerta del Mar, Cádiz, Spain |
| 864 |
Infection Rates in HIV/HCV and HCV Patients Treated with Interferon Are Similar and not Related to Neutropenia
Curtis L Cooper*, S Al-Bedwawi, C Lee, and G Garber
Univ of Ottawa, Ottawa Hosp, Canada |
|
